LAM-001 not checked

IRulya Therapeutics Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Sarcoidosis Associated Pulmonary Hypertension
Main trialPhase 2
“A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD).”In the company’s words, NCT05798923 on ClinicalTrials.gov

Other drugs for Pulmonary Hypertension Due to Lung Diseases and Hypoxia

All 5 drugs for Pulmonary Hypertension Due to Lung Diseases and Hypoxia

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Mar 2028 LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Phase 2Not yet recruiting Dec 2028 LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow LAM-001

Following is part of Solo: you see every change to LAM-001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in